School of Pharmacy, Shanxi Medical University, 56 Xinjian South Road, Taiyuan030001, Shanxi, China.
Parasitology. 2020 Jan;147(1):58-64. doi: 10.1017/S0031182019001306. Epub 2019 Sep 26.
It is urgent to develop new antimalarial drugs with good therapeutic effects to address the emergence of drug resistance. Here, the artelinic acid-choline derivative (AD) was synthesized by dehydration reaction and esterification reaction, aimed to avoid the emergence of drug resistance by synergistic effect of artemisinins and choline derivative, which could compete with choline for rate-limiting enzymes in the phosphatidylcholine (PC) biosynthetic pathway. AD was formulated into liposomes (ADLs) by the thin-film hydration method. Efficacy of ADLs was evaluated by Peters 4-day suppression test. The suppression percentage against Plasmodium yoelii BY265 (PyBY265) in ADLs group was higher than those of positive control groups (dihydroartemisinin liposomes, P < 0.05) and other control groups (P ⩽ 0.05) at the doses of 4.4, 8.8, 17.6 µmol (kg·d)-1, respectively. The negative conversion fraction, recrudescence fraction and survival fraction of ADLs group were superior to other control groups. Pharmacokinetics in rats after intravenous injection suggested that ADLs exhibited higher exposure levels (indexed by area under concentration-time curve) than that of AD solution, artelinic acid liposomes or artelinic acid solution (P < 0.01). Taken together, ADLs exhibited promising antimalarial efficacy and pharmacokinetic characteristics.
迫切需要开发具有良好治疗效果的新型抗疟药物,以应对耐药性的出现。在这里,通过脱水反应和酯化反应合成了青蒿酸-胆碱衍生物(AD),旨在通过青蒿素和胆碱衍生物的协同作用避免耐药性的出现,该衍生物可以与胆碱竞争磷酰胆碱(PC)生物合成途径中的限速酶。通过薄膜水化法将 AD 制成脂质体(ADLs)。通过彼得斯 4 天抑制试验评估 ADLs 的疗效。在 4.4、8.8、17.6 µmol(kg·d)-1剂量下,ADLs 组对 Plasmodium yoelii BY265(PyBY265)的抑制率均高于阳性对照组(双氢青蒿素脂质体,P < 0.05)和其他对照组(P ⩽ 0.05)。ADLs 组的阴转率、复燃率和存活率均优于其他对照组。大鼠静脉注射后的药代动力学研究表明,ADLs 的暴露水平(以浓度-时间曲线下面积为指标)高于 AD 溶液、青蒿酸脂质体或青蒿酸溶液(P < 0.01)。综上所述,ADLs 表现出有前景的抗疟疗效和药代动力学特征。